XEOMIN® Safety | Adults with Upper Limb Spasticity

Adults With Upper Limb Spasticity

Demonstrated Safety in Adults With Upper Limb Spasticity

Adverse Reactions Pinch to zoom
  • In 2 clinical trials with total doses of 400 Units, most patients experienced mild to moderate adverse reactions1,2

References

  1. Elovic EP, Munin MC, Kañovský P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo–controlled trial of incobotulinumtoxinA for upper–limb post–stroke spasticity. Muscle Nerve. 2016;53(3):415-421.
  2. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.